The global hepatitis therapeutics market size was USD 14.50 Bn in 2022 and is likely to reach USD 19.72 Bn by 2031, expanding at a CAGR of 3.2% during 2023–2031. The market growth is attributed to the rising cases of autoimmune illnesses and the increasing incidence of viral hepatitis.
When inflammation occurs in the liver of an individual, it is known as hepatitis. This disease is commonly caused due to the hepatitis virus. However, other reasons for causing hepatitis are autoimmune diseases, infections, medication errors, and toxic substances including drugs, alcohol, and others.
Globally, over 1.34 million individuals died as a result of this disease in 2015. The number of death caused by HIV and tuberculosis are significantly less in number when compared to the number of deaths caused by hepatitis. The number of deaths caused by HIV and tuberculosis, on the other hand, is decreasing, but the rate of death caused by viral hepatitis is increasing.
According to the World Health Organization, approximately 1.4 million individuals die each year from hepatitis, and around 400 million people are infected with at least one form of the disease. This ailment is divided into two forms based on the length of time the patient is afflicted.
When this condition lasts less than six months, it is classed as acute; when it lasts longer than six months, it is classified as chronic. Hepatitis A Virus (HAV) is transferred through drinking contaminated water, eating contaminated food, or coming into touch with an infected individual.
According to the estimations of WHO, 90 percent of children in developing nations are infected with the virus before they reach the age of ten, owing to insufficient hygiene and sanitation.
The market report finds that the COVID-19 pandemic has negatively impacted the growth of the hepatitis therapeutics market size. Patients with hepatitis have faced new difficulties in getting clinical treatment and consideration due to the continuous delays in routine hepatitis.
Hepatitis Therapeutics Market Dynamics
The global hepatitis therapeutics market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance during 2023 to 2031.
Drivers
Increasing research and development activities are expected to drive the growth of the hepatitis therapeutics market. Increasing research activities for the pipeline development of potent drugs are growing rapidly in the market. However, the introduction and emergence of generic versions of hepatitis C virus (HCV) medicines in the market are estimated to drive the market over the forecast period. Increasing patient awareness about advanced therapeutics and making improvements to healthcare facilities are anticipated to boost the market growth during the forecast period.
Restraints
Due to high medicine prices, access to therapies for this disease has been limited to individuals with a high-income level, which may function as a constraining factor for this market. Hepatitis medicines are costly as the manufacturing companies are using expensive raw materials such as active pharmaceuticals ingredients (APIs) and pharmacological intermediates, which is restraining the growth of the market. However, the expiration of the patent on the branded version of the drug, as well as the side effects of the drug, resulting in the drug's discontinuation is anticipated to hinder the market growth.
Opportunities
Growth opportunities in emerging countries and sectors are expected to create lucrative opportunities for the growth of the market. The availability of improved healthcare infrastructure is a growth opportunity for the market.
Scope of Hepatitis Therapeutics Market Report
The global hepatitis therapeutics market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Hepatitis Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2020–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, and Others), Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers), and Drug Class (Oral Antivirals and Immune Modulators)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Johnson & Johnson Services, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; AbbVie Inc.; GSK plc.; F. Hoffmann-La Roche Ltd; Lupin Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; and Zydus Group.
|
Hepatitis Therapeutics Market Segment Insights
Based on disease type, the hepatitis therapeutics market is segmented into hepatitis A, hepatitis B, hepatitis C, and others. The hepatitis B segment is projected to account for a large market share during the forecast period, owing to the high prevalence of hepatitis B. To replicate and proliferate in the body, the Hepatitis D virus (HDV) requires the assistance of the hepatitis B virus (HBV). The HDV virus is a Ribonucleic Acid virus.
Globally, approximately 15 million people are co-infected with HDV and HBV, and no effective HDV medication is currently available. As a result, immunization against HBV is strongly advised to prevent both hepatitis B and D. This is one of the primary factors influencing the market's current revenue share.
HCV causes a variety of major problems as compared to hepatitis A and B. HCV infects around 130 to 150 million persons worldwide, according to the estimations of WHO. Furthermore, a large percentage of HCV-infected patients develop liver cirrhosis or cancer, and approximately 700,000 individuals die as a result of these diseases. The above-mentioned factor is expected to drive the demand for HCV medications in the coming years.
One of the primary drivers contributing to the market growth is the introduction of technologically enhanced medicinal solutions for the treatment of hepatitis. Hepatitis C was previously incurable, but with the advent of drugs like Sovaldi and Harvoni in 2013 and 2014, respectively, the treatment rate has risen dramatically in recent years. According to reports, these treatments sold for more than USD 19.1 billion in 2015, and demand for these drugs is projected to stay robust in the coming years.
On the basis of distribution channel, the market is divided into drug stores & retail pharmacies, hospital pharmacies, and online providers. The drug stores & retail pharmacies segment is projected to register a considerable CAGR during the forecast period, due to the increasing availability of both branded and generic medications.
Based on Drug Class, the hepatitis therapeutics market is segregated into oral antivirals and immune modulators. The oral antivirals segment is expected to register a robust growth rate during the forecast period, due to the increasing demand for novel drugs and the approval of new drugs. Antiviral drugs destroy the ability of the virus to reproduce thus, the amount of virus in the bloodstream decreases.
In terms of region, the global hepatitis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, owing to high demand in the United States, somewhat lower patient affordability, and increased awareness of advanced treatments in the region. Some of the important factors contributing to the high share are the presence of favorable reimbursement policies, the availability of well-developed healthcare infrastructure, and access to the latest medicines available for treatment.
The Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to the rising demand for generic pharmaceuticals. Gilead has granted licenses to seven Indian producers to deliver hepatitis medications to various parts of the world. More than half of the HCV-infected population lives in the countries covered by this agreement.
The Medicine Patent Pool's varied licenses allow multiple manufacturers to develop generic versions of these HCV treatments even while the drugs are patented, which is predicted to have an impact on the market over the forecast period due to lower drug prices and higher consumption rates.
Middle East & Africa and Latin America are expected to grow rapidly in the coming years, due to the high prevalence rates and an increase in the import of generic drugs to treat various hepatitis disorders. Different manufacturers are developing their businesses in MEA and Latin America to cater to the large unmet demands for improved treatment as the patient population in the United States and other developed regions declines, due to the beneficial results of employing HCV medications.
Segments
The global hepatitis therapeutics market has been segmented on the basis of
Disease Type
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Others
Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
Drug Class
- Oral Antivirals
- Immune Modulators
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global hepatitis therapeutics market are Johnson & Johnson Services, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; AbbVie Inc.; GSK plc.; F. Hoffmann-La Roche Ltd; Lupin Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; and Zydus Group.
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
- In March 2021, Dicerna Pharmaceuticals announced that Roche has initiated RG6346 in Phase 2 Combination Trial for the treatment of chronic hepatitis B virus (HBV) infection. The phase 2 platform trial evaluates the efficacy and safety of RG634 in combination with multiple additional with multiple agents with different mechanisms of action.
Request For Customization
Enquiry Before Buying
Speak With Analyst
